Skip to content
Companies

Jasper Therapeutics

Antibody drugs for chronic hives and rare immune diseases

Raised to date

$132M

of $132M offered across 1 Form D filing

Investors
40
Last filed
Aug 4, 2026

About

Jasper Therapeutics is a clinical-stage biotechnology company in Redwood City, California developing antibody therapies for immune-mediated and rare diseases. Its lead legacy asset, briquilimab, is an aglycosylated monoclonal antibody that blocks stem cell factor from binding the KIT (CD117) receptor, depleting mast cells and hematopoietic stem cells through apoptosis. In July 2026 Jasper acquired Kira Pharmaceuticals in an all-stock deal, adding a complement-inhibition and B-cell pipeline and a second site in Cambridge, Massachusetts. The company was incorporated in Delaware in 2018 and went public in 2021 via a merger with Amplitude Healthcare Acquisition Corporation.

Briquilimab is a targeted anti-KIT antibody that removes the mast cells causing the inflammatory response rather than suppressing downstream mediators, with a demonstrated efficacy and safety profile across more than 160 dosed subjects and healthy volunteers.

Funding

  • EquityFiled Aug 4, 2026Form D
    $132M/ $132M

Product

Briquilimab

Monoclonal antibody therapeutic

An investigational aglycosylated monoclonal antibody targeting KIT (CD117) that blocks stem cell factor signaling and depletes mast cells and hematopoietic stem cells via apoptosis, in development for chronic urticaria and progressing toward a pre-BLA meeting in severe combined immunodeficiency (SCID).

  • Targets KIT (CD117) and blocks stem cell factor binding
  • Aglycosylated antibody format
  • Depletes mast cells through apoptosis

Built for

Patients with mast cell driven and complement-mediated diseases — chronic spontaneous and inducible urticaria, asthma, paroxysmal nocturnal hemoglobinuria, rare renal disease, and SCID — reached through allergists, immunologists, hematologists, and transplant centers

People on file